BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax of $18.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2018-09-30 was $18.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2018-06-30 was $83.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2018-03-31 was -$38.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2017-12-31 was -$20.00M, a 110.31% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2017 was -$101.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2016 was -$5.00M, a 108.47% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2015 was $59.00M, a 57.55% decline from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2014 was $139.00M, a 139.66% increase from fiscal 2013.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 12 month |
|---|---|---|---|---|
| 2018-09-30 | $18.00M 10-Q · filed 2018-10-25 | $101.00M derived: sum of 2 quarters · filed 2018-10-25 | $63.00M 10-Q · filed 2018-10-25 | $43.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-06-30 | $83.00M 10-Q · filed 2018-07-26 | $45.00M 10-Q · filed 2018-07-26 | $25.00M derived: sum of 3 quarters · filed 2018-07-26 | -$3.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-03-31 | -$38.00M 10-Q · filed 2018-04-26 | -$58.00M derived: sum of 2 quarters · filed 2018-04-26 | -$86.00M derived: sum of 3 quarters · filed 2018-10-25 | -$121.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$48.00M derived: sum of 2 quarters · filed 2018-10-25 | -$83.00M derived: sum of 3 quarters · filed 2018-10-25 | -$101.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | -$28.00M 10-Q · filed 2018-10-25 | -$63.00M derived: sum of 2 quarters · filed 2018-10-25 | -$81.00M 10-Q · filed 2018-10-25 | $113.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-06-30 | -$35.00M 10-Q · filed 2018-07-26 | -$53.00M 10-Q · filed 2018-07-26 | $141.00M derived: sum of 3 quarters · filed 2018-07-26 | $127.00M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | -$18.00M 10-Q · filed 2018-04-26 | $176.00M derived: sum of 2 quarters · filed 2018-04-26 | $162.00M derived: sum of 3 quarters · filed 2018-04-26 | $103.00M derived: sum of 4 quarters · filed 2018-04-26 |
| 2016-12-31 | $194.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $180.00M derived: sum of 2 quarters · filed 2018-02-13 | $121.00M derived: sum of 3 quarters · filed 2018-02-13 | -$5.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | -$14.00M 10-Q · filed 2017-10-26 | -$73.00M derived: sum of 2 quarters · filed 2017-10-26 | -$199.00M 10-Q · filed 2017-10-26 | -$176.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | -$59.00M 10-Q · filed 2017-07-27 | -$185.00M 10-Q · filed 2017-07-27 | -$162.00M derived: sum of 3 quarters · filed 2018-02-13 | -$196.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | -$126.00M 10-Q · filed 2017-04-27 | -$103.00M derived: sum of 2 quarters · filed 2018-02-13 | -$137.00M derived: sum of 3 quarters · filed 2018-02-13 | -$102.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$11.00M derived: sum of 2 quarters · filed 2018-02-13 | $24.00M derived: sum of 3 quarters · filed 2018-02-13 | $59.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | -$34.00M 10-Q · filed 2016-10-27 | $1.00M derived: sum of 2 quarters · filed 2016-10-27 | $36.00M 10-Q · filed 2016-10-27 | $98.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $35.00M 10-Q · filed 2016-07-28 | $70.00M 10-Q · filed 2016-07-28 | $132.00M derived: sum of 3 quarters · filed 2017-02-21 | $228.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $35.00M 10-Q · filed 2016-04-28 | $97.00M derived: sum of 2 quarters · filed 2017-02-21 | $193.00M derived: sum of 3 quarters · filed 2017-02-21 | $179.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $158.00M derived: sum of 2 quarters · filed 2017-02-21 | $144.00M derived: sum of 3 quarters · filed 2017-02-21 | $139.00M 10-K · filed 2017-02-21 |
| 2014-09-30 | $96.00M 10-Q · filed 2015-10-27 | $82.00M derived: sum of 2 quarters · filed 2015-10-27 | $77.00M 10-Q · filed 2015-10-27 | $75.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$14.00M 10-Q · filed 2015-07-23 | -$19.00M 10-Q · filed 2015-07-23 | -$21.00M derived: sum of 3 quarters · filed 2016-02-12 | -$60.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | -$5.00M 10-Q · filed 2015-04-28 | -$7.00M derived: sum of 2 quarters · filed 2016-02-12 | -$46.00M derived: sum of 3 quarters · filed 2016-02-12 | -$16.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$41.00M derived: sum of 2 quarters · filed 2016-02-12 | -$11.00M derived: sum of 3 quarters · filed 2016-02-12 | $58.00M 10-K · filed 2016-02-12 |
| 2013-09-30 | -$39.00M 10-Q · filed 2014-10-24 | -$9.00M derived: sum of 2 quarters · filed 2014-10-24 | $60.00M 10-Q · filed 2014-10-24 | $77.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $30.00M 10-Q · filed 2014-07-24 | $99.00M 10-Q · filed 2014-07-24 | $116.00M derived: sum of 3 quarters · filed 2015-02-13 | $81.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $69.00M 10-Q · filed 2014-04-29 | $86.00M derived: sum of 2 quarters · filed 2015-02-13 | $51.00M derived: sum of 3 quarters · filed 2015-02-13 | $81.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$18.00M derived: sum of 2 quarters · filed 2015-02-13 | $12.00M derived: sum of 3 quarters · filed 2015-02-13 | $26.00M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$35.00M 10-Q · filed 2013-10-23 | -$5.00M derived: sum of 2 quarters · filed 2013-10-23 | $9.00M 10-Q · filed 2013-10-23 | |
| 2012-06-30 | $30.00M 10-Q · filed 2013-07-25 | $44.00M 10-Q · filed 2013-07-25 | ||
| 2012-03-31 | $14.00M 10-Q · filed 2013-04-25 | |||
| 2011-12-31 | $28.00M 10-K · filed 2014-02-14 | |||
| 2010-12-31 | $18.00M 10-K · filed 2013-02-15 | |||
| 2009-12-31 | -$28.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |